Effects of resibufogenin in experimental hypertension

American Journal of Nephrology

Volumn 28, Issue 1, 2007, Pages 8-13

  Danchuk, S ^a   Sukhanov, S ^a   Horvat, D ^b   Uddin, M N ^b   Puschett, J B ^a,b,c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Angiotensinogen; Experimental hypertension; Marinobufagenin; Resibufogenin; Volume expansion

Indexed keywords

ANGIOTENSIN; BUFOGENIN; DEOXYCORTICOSTERONE ACETATE; SODIUM CHLORIDE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; URINARY EXCRETION;

ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; BUFANOLIDES; CREATININE; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; HYPERTENSION, RENAL; MALE; MINERALOCORTICOIDS; PROTEINURIA; RATS; RATS, INBRED STRAINS; SODIUM CHLORIDE; SUPEROXIDES; VASOCONSTRICTOR AGENTS;

EID: 36248934281     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108756     Document Type: Article

References (35)

1. Selye H: Production of nephrosclerosis by overdosage with desoxycorticosterone acetate. Can Med Assoc J 1942;47:515-519.
2. Sun Z, Zhang Z: Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin 2005;26:295-301.
3. Katholi RE, Naftilan AJ, Oparil S: Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. Hypertension 1980;2:266-273.
4. + balance, volume, and blood pressure homeostasis in intact and ovariectomized deoxycorticosterone-acetate salt rats. Hypertension 2006;47:1101-1107.
5. Zou L, Hymel A, Imig JD, Navar LG: Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. Hypertension 1996;27:658-662.
6. Ianosi-Irimie MR, Vu HV, Whitbred JM, Pridjian CA, Nadig JD, Williams MY, Wrenn, DC, Pridjian G, Puschett JB: A rat model of preeclampsia. Clin Exp Hypertens 2005;27:605-617.
7. Vu HV, Ianosi-Irimie MR, Pridjian CA, Whitbred JM, Durst JM, Bagrov AY, Fedorova OV, Pridjian G, Puschett JB: Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005;25:520-528.
8. Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002;269:2440-2448.
9. Pamnani MB, Chen S, Yuan CM, Haddy FJ: Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats. Hypertension 1994;23(1 suppl):I106-I109.
10. Vu HV, Ianosi-Irimie MR, Danchuk S, Rabon E, Nogawa T, Kamano Y, Pettit GR, Wiese T, Puschett JB: Resibufogenin corrects hypertension in a rat model of human preeclampsia. Exp Biol Med (Maywood) 2006;231:215-220.
11. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG: Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003;41:42-49.
12. Kobori H, Harrison-Bernard LM, Navar LG: Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002;61:579-585.
13. Nasir UM, Iwanaga S, Nabi AH, Urayama O, Hayashi K, Hayashi T, Kawai K, Sultana A, Murakami K, Suzuki F: Laughter therapy modulates the parameters of renin-angiotensin system in patients with type 2 diabetes. Int J Mol Med 2005;16:1077-1081.
14. Kato H, Ishida J, Imagawa S, Saito T, Suzuki N, Matsuoka T, Sugaya T, Tanimoto K, Yokoo T, Ohneda O, Sugiyama F, Yagami K, Fujita T, Yamamoto M, Nangaku M, Fukamizu A: Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J 2005;19:2023-2025.
15. Dahl LK, Knudsen KD, Heine M, Leitl G: Effects of chronic excess salt ingestion. Genetic influence on the development of salt hypertension in parabiotic rats: evidence for a humoral factor. J Exp Med 1967;126:687-699.
16. de Wardener HE, Mills IH, Clapham WF, Hayter CJ: Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci 1961;21:249-258.
17. Haddy FS, Overbeck HW: The role of humoral agents in volume expanded hypertension. Life Sci 1976;19:935-948.
18. Blaustein MP: Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol 1977;232:C165-C173.
19. +)ATPase associated with essential hypertension. Nature 1982;300:650-652.
20. Hamlyn JM, Lu ZR, Manunta P, Ludens JH, Kimura K, Shah JR, Laredo J, Hamilton JP, Hamilton MJ, Hamilton BP: Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin Exp Hypertens 1998;20:523-533.
21. 2+ stores and cell responsiveness. Am J Physiol 1993;264(6 Pt 1):C1367-C1387.
22. Schoner W, Scheiner-Bobis G: Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin Nephrol 2005;25:343-351.
23. Gonick HC, Ding Y, Vaziri ND, Bagrov AY, Fedorova OV: Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998;20:617-627.
24. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE: Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 1996;31:296-305.
25. Fedorova OV, Doris PA, Bagrov AY: Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin Exp Hypertens 1998;20:581-591.
26. Fedorova OV, Anderson DE, Lakatta EG, Bagrov AY: Interaction of NaCl and behavioral stress on endogenous sodium pump ligands in rats. Am J Physiol Regul Integr Comp Physiol 2001;281:R352-R358.
27. Fedorova OV, Kolodkin NI, Agalakova NI, Lakatta EG, Bagrov AY: Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 2001;37(2 Pt 2):462-466.
28. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY: Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999;17:1179-1187.
29. Romero JC, Reckelhoff JF: Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999;34:943-949.
30. Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005;289:R913-R935.
31. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
32. Alper AB, Outland J, Finigan K, Pridjian G, Aina-Mumuney A, Puschett JB: Phenotypic characteristics shared by preeclamptic patients and an animal model of the syndrome: report of a pilot study. Am J Hypertens 2006;19:947-950.
33. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A: Urinary angiotensinogen as a marker of intrarenal angiotensinogen II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007;18:1558-1565.
34. Kobori H, Harrison-Bernard LM, Navar LG: Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 2001;12:431-439.
35. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS: Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997;273(1 Pt 2):F170-F177.